Acorda Therapeutics, Inc. (ACOR) Upgraded to Sell at Goldman Sachs Group, Inc. (The)

Goldman Sachs Group, Inc. (The) upgraded shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) from a conviction sell rating to a sell rating in a research note published on Wednesday morning.

Several other research firms have also commented on ACOR. J P Morgan Chase & Co set a $32.00 price objective on shares of Acorda Therapeutics and gave the stock a buy rating in a research note on Thursday, February 9th. Cantor Fitzgerald reaffirmed a neutral rating on shares of Acorda Therapeutics in a research note on Wednesday, December 21st. Cowen and Company set a $60.00 price objective on shares of Acorda Therapeutics and gave the stock a buy rating in a research note on Tuesday, January 3rd. Janney Montgomery Scott started coverage on shares of Acorda Therapeutics in a research note on Monday, December 19th. They set a neutral rating and a $23.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Acorda Therapeutics from a buy rating to a hold rating in a research note on Monday, January 23rd. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $33.80.

Acorda Therapeutics (NASDAQ:ACOR) opened at 23.85 on Wednesday. The company’s market capitalization is $1.10 billion. Acorda Therapeutics has a one year low of $16.40 and a one year high of $37.36. The firm has a 50-day moving average of $20.98 and a 200 day moving average of $21.67.

Acorda Therapeutics (NASDAQ:ACOR) last posted its earnings results on Tuesday, February 14th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by $0.06. Acorda Therapeutics had a negative net margin of 4.38% and a negative return on equity of 1.66%. The business earned $140.63 million during the quarter, compared to analysts’ expectations of $137.90 million. During the same period last year, the business posted $0.28 earnings per share. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. Equities research analysts predict that Acorda Therapeutics will post $0.24 earnings per share for the current fiscal year.

This piece of content was first reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece of content can be read at https://baseballnewssource.com/markets/acorda-therapeutics-inc-acor-upgraded-to-sell-at-goldman-sachs-group-inc-the/434971.html.

In related news, insider Ron Cohen sold 40,172 shares of the company’s stock in a transaction that occurred on Wednesday, December 14th. The stock was sold at an average price of $20.75, for a total value of $833,569.00. Following the sale, the insider now owns 519,860 shares in the company, valued at $10,787,095. The sale was disclosed in a legal filing with the SEC, which is available through this link. 8.00% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System raised its stake in Acorda Therapeutics by 0.5% in the second quarter. Louisiana State Employees Retirement System now owns 20,400 shares of the biopharmaceutical company’s stock valued at $520,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in Acorda Therapeutics by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 10,220 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 160 shares in the last quarter. Nationwide Fund Advisors raised its stake in Acorda Therapeutics by 1.1% in the second quarter. Nationwide Fund Advisors now owns 38,917 shares of the biopharmaceutical company’s stock valued at $993,000 after buying an additional 431 shares in the last quarter. Quantbot Technologies LP raised its stake in Acorda Therapeutics by 5.3% in the third quarter. Quantbot Technologies LP now owns 16,315 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 821 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in Acorda Therapeutics by 17.4% in the second quarter. Teacher Retirement System of Texas now owns 6,236 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 925 shares in the last quarter.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza.

5 Day Chart for NASDAQ:ACOR

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with our FREE daily email newsletter.

 

Latest News

Alex Rodriguez: No Comeback for Me
Alex Rodriguez: No Comeback for Me
Cleveland Indians Moving Along Slowly with Corey Kluber
Cleveland Indians Moving Along Slowly with Corey Kluber
Garrett Richards Returns Without Tommy John Surgery
Garrett Richards Returns Without Tommy John Surgery
Chris Tillman Injury Will Test Rotation Depth with Orioles
Chris Tillman Injury Will Test Rotation Depth with Orioles
Brandon Phillips Traded to Atlanta by Cincinnati
Brandon Phillips Traded to Atlanta by Cincinnati
Rumor: Miami Marlins Reach Tentative Agreement to Sell
Rumor: Miami Marlins Reach Tentative Agreement to Sell


Leave a Reply

 
© 2006-2017 BBNS.